< Back to previous page
Researcher
Lise Heylen
- Disciplines:Drug discovery and development not elsewhere classified
Affiliations
- Molecular Biodiscovery (Division)
Member
From15 Oct 2019 → Today
Projects
1 - 1 of 1
- An antisense strategy and network pharmacology approach in zebrafish models to identify novel targets for pharmacoresistant epilepsyFrom1 Nov 2019 → 30 Sep 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 5 of 5
- Hyperactivation of mTORC1 in a double hit mutant zebrafish model of tuberous sclerosis complex causes increased seizure susceptibility and neurodevelopmental abnormalities(2022)
Authors: Ann-Sofie De Meulemeester, Lise Heylen, Aleksandra Siekierska, Peter de Witte
- Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery(2022)
Authors: Lise Heylen, Michèle Partoens, Peter de Witte, Aleksandra Siekierska
- Pericardial Injection of Kainic Acid Induces a Chronic Epileptic State in Larval Zebrafish(2021)
Authors: Lise Heylen, Ann-Sofie De Meulemeester, Daniëlle Copmans, Youcef Kazwiny, Pieter Vanden Berghe, Peter de Witte, Aleksandra Siekierska
- Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects(2020)
Authors: Marjolein Ensinck, Liesbeth De Keersmaecker, Lise Heylen, Anabela Santo Ramalho Venâncio, Rik Gijsbers, Ricard Farré Marti, Christiane De Boeck, Frauke Christ, Zeger Debyser, Marianne Carlon
Pages: 1 - 14 - Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects(2020)
Authors: Marjolein Ensinck, Lise Heylen, Rik Gijsbers, Christiane De Boeck, Frauke Christ, Zeger Debyser, Marianne Carlon
Pages: 1 - 14